MX2021005453A - Tratamiento de combinacion para hipertension resistente. - Google Patents

Tratamiento de combinacion para hipertension resistente.

Info

Publication number
MX2021005453A
MX2021005453A MX2021005453A MX2021005453A MX2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A MX 2021005453 A MX2021005453 A MX 2021005453A
Authority
MX
Mexico
Prior art keywords
combination treatment
resistant hypertension
hypertension
combination
resistant
Prior art date
Application number
MX2021005453A
Other languages
English (en)
Spanish (es)
Inventor
Jr John C Burnett
Nina Dzhoyashvili
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of MX2021005453A publication Critical patent/MX2021005453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021005453A 2018-11-09 2019-11-08 Tratamiento de combinacion para hipertension resistente. MX2021005453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862758009P 2018-11-09 2018-11-09
PCT/US2019/060401 WO2020097421A1 (en) 2018-11-09 2019-11-08 Combination treatment for resistant hypertension

Publications (1)

Publication Number Publication Date
MX2021005453A true MX2021005453A (es) 2021-09-08

Family

ID=70612496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005453A MX2021005453A (es) 2018-11-09 2019-11-08 Tratamiento de combinacion para hipertension resistente.

Country Status (13)

Country Link
US (2) US20220118054A1 (cg-RX-API-DMAC7.html)
EP (2) EP3877402B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022506716A (cg-RX-API-DMAC7.html)
KR (1) KR20210090229A (cg-RX-API-DMAC7.html)
CN (1) CN113727997A (cg-RX-API-DMAC7.html)
AU (2) AU2019375988A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008841A2 (cg-RX-API-DMAC7.html)
CA (1) CA3119055A1 (cg-RX-API-DMAC7.html)
ES (1) ES3047085T3 (cg-RX-API-DMAC7.html)
IL (2) IL282958B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021005453A (cg-RX-API-DMAC7.html)
PL (1) PL3877402T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020097421A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023039392A1 (en) * 2021-09-07 2023-03-16 Mayo Foundation For Medical Education And Research Methods and materials for determining pgc target dosage
WO2023039453A2 (en) * 2021-09-09 2023-03-16 Mayo Foundation For Medical Education And Research Dual-function polypeptides and methods for use thereof
US20240116990A1 (en) * 2022-09-19 2024-04-11 Mayo Foundation For Medical Education And Research Compositions and Methods of Treatment Using CRRL 191
WO2024178072A1 (en) * 2023-02-22 2024-08-29 Mayo Foundation For Medical Education And Research Methods of treating hypertension with metabolic syndrome using manp
KR20260074307A (ko) * 2023-09-05 2026-05-22 이-스타 바이오텍, 엘엘씨 Manp의 제형 및 이의 용도
WO2025184377A1 (en) * 2024-02-28 2025-09-04 Mayo Foundation For Medical Education And Research Methods for sustained lowering of blood pressure using manp

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161521A (en) 1975-08-08 1979-07-17 Merck & Co., Inc. Somatostatin analogs
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
US6312679B1 (en) 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US4935492A (en) 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4004430A1 (de) 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
KR930009516B1 (ko) 1990-04-27 1993-10-06 미쓰비시덴키 가부시키가이샤 진동검출기 및 그의 고유진동주파수 조정방법
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US6410044B1 (en) 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
US6969480B2 (en) 2000-05-12 2005-11-29 Matregen Corp. Method of producing structures using centrifugal forces
SG159387A1 (en) 2002-11-26 2010-03-30 Biocon Ltd In Modified natriuretic compounds, conjugates, and uses thereof
ES2323141T3 (es) 2004-08-12 2009-07-07 Quest Pharmaceutical Services Composiciones farmaceuticas para el suministro por liberacion controlada de compuestos biologicamente activos.
WO2008061355A1 (en) 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
US20100266704A1 (en) 2008-12-15 2010-10-21 Novartis Ag Octreotide depot formulation with constantly high exposure levels
AU2015230666A1 (en) * 2014-03-14 2016-10-20 Madeleine Pharmaceuticals Pty Ltd Adjuvant therapy to standard of care (SOC) diuretic treatment
PL3538131T3 (pl) * 2016-11-09 2025-09-08 Mayo Foundation For Medical Education And Research Analogi MANP

Also Published As

Publication number Publication date
CN113727997A (zh) 2021-11-30
EP3877402B1 (en) 2025-07-16
IL282958B2 (en) 2025-01-01
JP2022506716A (ja) 2022-01-17
AU2025203575A1 (en) 2025-06-05
IL282958A (en) 2021-06-30
IL315007A (en) 2024-10-01
US20250381249A1 (en) 2025-12-18
BR112021008841A2 (pt) 2021-08-31
AU2019375988A1 (en) 2021-05-27
ES3047085T3 (en) 2025-12-03
JP2024156691A (ja) 2024-11-06
EP3877402A4 (en) 2022-07-27
PL3877402T3 (pl) 2025-12-01
IL315007B1 (en) 2026-06-01
EP3877402A1 (en) 2021-09-15
WO2020097421A1 (en) 2020-05-14
KR20210090229A (ko) 2021-07-19
EP4603090A1 (en) 2025-08-20
CA3119055A1 (en) 2020-05-14
US20220118054A1 (en) 2022-04-21
IL282958B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
CO2018013104A2 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso
MY199751A (en) Anti-igf-i receptor antibody
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
WO2020061229A3 (en) Arc-based capsids and uses thereof
UY37834A (es) Tratamiento de mh con compuestos de pirimidinadiona
EA202190822A1 (ru) Технологии для выполнения действий на основе обнаружения объектов
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MX2019013990A (es) Estructura de refuerzo para suelos y método relacionado.
UY37576A (es) Anticuerpos dirigidos a hueso
MX2022001027A (es) Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.
MX2020013214A (es) Actualizacion de graficos ejecutables.
PE20230381A1 (es) Proteina de union a rgma
MX2024012294A (es) RECEPTORES DE TGF-ß Y MÉTODOS DE USO
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
WO2020092672A3 (en) A quantitative algorithm for endometriosis
EP4620524A3 (en) Compositions for the treatment of hypertension
MX384037B (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX2020003644A (es) Metodo de martillado de union soldada con filete a solape y estructuras soldadas.
CO2025015637A2 (es) Quinoxalinas sustituidas
UY38385A (es) Concentrado y aislado de cannabinoide, método para su obtención y uso
MX2025000236A (es) Composiciones para el tratamiento de hipertension
ZA202007896B (en) Wear part, bucket, system and method
CL2019003754A1 (es) Dispositivo y método para el tratamiento del mosto.
EP4596720A3 (en) Bacterial leader sequences for periplasmic protein expression